Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Rating of "Moderate Buy" by Analysts

Shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $6.10.

Several equities research analysts have weighed in on the company. Citigroup dropped their price objective on Applied Therapeutics from $13.00 to $8.00 and set a "buy" rating for the company in a report on Friday, November 29th. UBS Group restated a "neutral" rating and set a $2.00 target price (down previously from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Robert W. Baird cut their price target on shares of Applied Therapeutics from $14.00 to $5.00 and set an "outperform" rating on the stock in a report on Friday, November 29th. William Blair downgraded shares of Applied Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, December 23rd. Finally, Royal Bank of Canada cut their target price on shares of Applied Therapeutics from $4.00 to $1.50 and set a "sector perform" rating on the stock in a research note on Friday, December 20th.

Institutional Trading of Applied Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd purchased a new position in Applied Therapeutics during the 3rd quarter valued at about $149,000. Intech Investment Management LLC bought a new position in shares of Applied Therapeutics during the third quarter valued at approximately $162,000. Ground Swell Capital LLC purchased a new position in shares of Applied Therapeutics during the fourth quarter valued at approximately $27,000. Toronto Dominion Bank bought a new stake in shares of Applied Therapeutics in the 4th quarter worth approximately $27,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Applied Therapeutics in the 2nd quarter worth approximately $172,000. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Stock Down 3.0 %

Shares of Applied Therapeutics stock traded down $0.02 during trading on Friday, reaching $0.57. 4,148,832 shares of the stock were exchanged, compared to its average volume of 4,953,123. The firm has a market cap of $66.56 million, a price-to-earnings ratio of -0.36 and a beta of 1.88. Applied Therapeutics has a 1 year low of $0.54 and a 1 year high of $10.62. The stock's fifty day moving average is $0.77 and its 200 day moving average is $4.91.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.